Worth Venture Partners, LLC Salarius Pharmaceuticals, Inc. Transaction History

Worth Venture Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$0.8 - $1.15 $339,840 - $488,519	-424,800 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.0 - $3.0 $64,244 - $192,732	64,244 Added 17.82%	424,800 $629,000
Q4 2020 Feb 17, 2021	BUY	$0.65 - $1.34 $66,499 - $137,091	102,307 Added 39.62%	360,556 $328,000
Q2 2020 Aug 14, 2020	SELL	$0.6 - $1.82 $27,658 - $83,898	-46,098 Reduced 15.15%	258,249 $341,000
Q1 2020 May 15, 2020	BUY	$0.56 - $3.82 $170,434 - $1.16 Million	304,347 New	304,347 $208,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.37M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Worth Venture Partners, LLC with notifications on news.